MARK2 and myocardial infarction: Pharmacologically targeting p38 MAPK or identifying downstream targets of the serine/threonine kinase that selectively suppress expression of the intermediate filament protein may represent a therapeutic approach to initiate a partial cardiac regenerative response post-MI secondary to the increased appearance of cycling nestin(+)-ventricular cardiomyocytes.